uniQure 48‑month AMT‑130 Huntington’s data show non‑significant 44% cUHDRS slowing vs external controls

 

uniQure 48‑month AMT‑130 Huntington’s data show non‑significant 44% cUHDRS slowing vs external controls as 36‑month data remain BLA basis

• High‑dose AMT‑130 patients showed 80% cUHDRS slowing at 36 months in Phase I/II Huntington’s trial.
• Data demonstrate sustained, dose‑dependent slowing of Huntington’s disease progression across 36‑ and 48‑month follow‑up.
• Company attributes lack of 48‑month statistical significance to survivor bias in the external control arm.

https://finviz.com/stock?t=QURE&p=d